Pitavastatin (Livazo) in the treatment of dyslipidemia in routine clinical practice in Russia. Russian programme "LEADER"

Abstract

Aim. To assess the effectiveness and adherence to therapy with pitavastatin (Livazo) in real clinical practice in Russia.
Materials and methods. The study was conducted between January 2018 and February 2019, in 135 leading and regional medical centers of Russia. Patients with primary hypercholesterolemia (and heterozygous familial hypercholesterolemia) with a high and very high risk level were included. Information on patients was recorded in the electronic medical system and contained data on the evaluation of the clinical status and risk factors of atherosclerosis, blood lipid parameters, including total cholesterol level (TC), low-density lipoprotein cholesterol (LDL-C) level, triglycerides (TG), high-density lipoprotein cholesterol level at baseline and at follow-up of pitavastatin (Livazo) treatment.
Results. A total number of 656 patients (pts) were included (mean age 59.9±10.3 years, 62.4 % females), 92% had concomitant diseases including arterial hypertension in 80%, coronary heart disease in 25%, diabetes mellitus 2 type in 8.4% of pts. Starting dose of pitavastatin in 57.5% of pts was 2 mg and therapy continued for 11.9±14.5 weeks. At next visit, after 12 weeks, in 72.3% of pts the dose of pitavastatin was not changed, in 25%, – was titrated to 4 mg. Administration of pitavastatin (Livazo) during 6 month follow up led to significant lowering of TC, LDL-C, TG levels and raise of HDL-C level, and the therapy was well tolerated. There were no significant side effects. LDL-C target level was reached in 237 (56%) pts of high risk and 30 (18%) of pts of very high risk.
Conclusion. Pitavastatin for 6 months has demonstrated high lipid-lowering efficacy and safety among patients with high and very high cardiovascular risk and primary hyperlipidemia.